GE Healthcare Technologies (GEHC) said Friday the NCCN clinical practice guidelines in oncology for doctors now recommend considering the use of fluoroestradiol, or FES, positron emission tomography, or PET, imaging in some individuals with lobular breast cancer.
The company said its cerianna injection is the only imaging agent approved by the US Food and Drug Administration to detect estrogen receptor positive breast cancer metastases, including lobular breast cancer.
GE Healthcare said invasive lobular cancer is the second most common type of breast cancer in the US.
Price: 70.05, Change: -1.48, Percent Change: -2.07
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。